A new startup wants to edit out the world’s biggest killer. Prominent cardiologist and geneticist Sekar Kathiresan is heading up a new company, Verve Therapeutics, that will develop gene-altering medicine to prevent heart attacks. Heart disease is the leading cause of death in the US and worldwide.
“Imagine an injection, once in life, that safely confers enduring protection against heart attack in adults,” said Kathiresan, the director of the Center for Genomic Medicine at Massachusetts General Hospital. He is stepping down from his posts at the hospital, the Broad Institute, and Harvard Medical School to run Verve full time in July…. Read more »
UNDERWRITERS AND PARTNERS
